After an R&D odyssey filled with setbacks, Clovis wins an FDA OK for rucaparib
Clovis Oncology $CLVS won some redemption today, gaining an accelerated approval for its first drug and setting it on a short path to commercialization.
The FDA has approved its PARP inhibitor rucaparib, to be sold as Rubraca, to treat ovarian cancer cases with BRCA mutations. The drug is entering a market that will be sliced and diced by a variety of competitors. The FoundationFocus CDxBRCA companion diagnostic was also OK’d for use with Rubraca.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.